Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin add-on to insulin in Chinese patients with type 2 diabetes mellitus
CTR20192710Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Jan 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20192710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192710.